Cantor Fitzgerald Forecasts Weaker Earnings for Verastem
Verastem, Inc. (NASDAQ:VSTM – Free Report) – Research analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for Verastem in a report issued on Tuesday, June 24th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the biopharmaceutical company will earn ($3.57) per share for the year, down from their prior estimate of ($3.24). The consensus […]
Verastem, Inc. (NASDAQ:VSTM – Free Report) – Research analysts at Cantor Fitzgerald reduced their FY2025 EPS estimates for Verastem in a report issued on Tuesday, June 24th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the biopharmaceutical company will earn ($3.57) per share for the year, down from their prior estimate of ($3.24). The consensus […]
